Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-03-27

FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for TRIUMEQ, a fixed-dose combination antiretroviral therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

SUPPL AP for TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)